Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2016 06:45 ET | Source: Lisata Therapeutics

Caladrius Biosciences Subsidiary PCT, LLC Enters Into Global Collaboration and License Agreement With Hitachi Chemical

Caladrius Sells 19.9% Equity Stake in PCT for $19.4 Million Licenses Cell Therapy Technology for Certain Asian Territories for $5.6 Million and Future Royalties BASKING RIDGE, N.J., March 14,...
March 08, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences to Host 2015 Fourth Quarter and Full Year Financial Results Conference Call on March 15 at 5:00 pm Eastern Time

BASKING RIDGE, N.J., March 08, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius”), a cell therapy company combining an industry-leading development and manufacturing...
February 17, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedical

BASKING RIDGE, N.J., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
January 28, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Announces Presentations at Upcoming Investor Conferences in February

BASKING RIDGE, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
January 13, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Announces Presentations at Multiple Upcoming Conferences in January

BASKING RIDGE, N.J., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
January 11, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Out-Licenses CD34 Technology to SPS Cardio, LLC for Chronic Heart Failure and Acute Myocardial Infarction

BASKING RIDGE, N.J., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
January 06, 2016 16:01 ET | Source: Lisata Therapeutics

Caladrius Tightens Strategic Focus and Provides 2016 Revenue Guidance

Emphasizes PCT subsidiary’s leadership position in the emerging cell therapy market with expectations for >30% revenue growth in 2016 Focuses clinical development on innovative platform of immune...
December 23, 2015 16:15 ET | Source: Lisata Therapeutics

UPDATE -- Caladrius Announces Changes to Its Board of Directors

BASKING RIDGE, N.J., Dec. 23, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (“Caladrius” or the “Company”) (NASDAQ:CLBS), a cell therapy company combining an industry-leading development...
December 23, 2015 07:30 ET | Source: Lisata Therapeutics

Caladrius Announces Changes to Its Board of Directors

BASKING RIDGE, N.J., Dec. 23, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (“Caladrius” or the “Company”) (NASDAQ:CLBS), a cell therapy company combining an industry-leading development...
December 01, 2015 07:30 ET | Source: Lisata Therapeutics

Caladrius Announces Publication of Two-Year Results From Phase 1 Trial of Type 1 Diabetes Product Candidate in Science Translational Medicine

BASKING RIDGE, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (“Caladrius” or the “Company”) (NASDAQ:CLBS), a cell therapy company combining an industry-leading external...